Rational generation of high-performance recombinant antibodies to post-translational modifications
Project Number1R21CA246457-01A1
Contact PI/Project LeaderHATTORI, TAKAMITSU
Awardee OrganizationNEW YORK UNIVERSITY SCHOOL OF MEDICINE
Description
Abstract Text
PROJECT SUMMARY
The overall goals of this project are to develop powerful technology that efficiently generates high-performance
and renewable antibodies to post-translational modifications (PTMs), and to make such reagents broadly
available to the research community. PTMs are chemical modifications of proteins that are important in many
cellular functions. Dysregulation of PTMs contributes to many diseases, including cancer. Antibodies to PTMs
are a central component in analyzing PTMs, but many available antibodies have severe shortcomings, limiting
the progress of biomedical and cancer research. Two major issues with available antibodies are low quality and
lot-to-lot variation, which could lead researchers to incorrect conclusions and contribute to a lack of reproducibility
in research results. Moreover, recent advances in proteomics and genomics have enabled comprehensive
studies that produce large datasets, and the community shares those results. Thus, the antibody problem has
become a world-wide problem affecting diverse research fields. The generation of antibodies with high specificity
and high affinity to PTMs is challenging, because they must discriminate small chemical changes in amino acids
and closely related amino acid sequences. To overcome fundamental difficulties in molecular recognition, we
propose an innovative approach built on our previous discovery of a unique antigen-binding mode of high-
performance antibodies to histone methylation. Conventionally, the antigen-binding fragment (Fab) of an
antibody recognizes its antigen with 1:1 stoichiometry. Our previous studies of antibodies to histone methylation
revealed an unexpected binding mechanism, which we dubbed “antigen clasping”, where two Fabs cooperatively
clasp one antigen by forming head-to-head homodimers. Antigen clasping creates exceptionally large antigen-
recognition surfaces, which enables antibodies to achieve high specificity and high affinity to PTMs. We
hypothesize that an approach to rationally generate antibodies that use antigen clasping will substantially
accelerate the development of high-performance antibodies to PTMs. Our specific aims are to establish a rational
approach for generating clasping antibodies, and to demonstrate the broad applicability of our approach by
generating clasping antibodies to phosphorylated antigens. We will critically validate clasping antibodies and
benchmark them against available antibodies. Primary products of this project will be recombinant proteins with
defined sequences, eliminating a major barrier to reproducibility. We envision that the proposed technology and
the high-performance reagents it produces will enable more robust and thorough analyses of PTMs and their
roles in diseases such as cancer.
Public Health Relevance Statement
NARRATIVE
Post-translational modifications of proteins play important roles in cellular process and their dysregulation is
associated with diseases including cancer. Antibodies to post-translational modifications are essential tools for
their analysis, but poor quality and lot-to-lot variation of many available antibodies limit the progress of
biomedical and cancer research. This project will establish a transformative technology for the efficient
generation of high-performance and renewable antibodies to post-translational modifications, which will
substantially accelerate biomedical and cancer research.
No Sub Projects information available for 1R21CA246457-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21CA246457-01A1
Patents
No Patents information available for 1R21CA246457-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21CA246457-01A1
Clinical Studies
No Clinical Studies information available for 1R21CA246457-01A1
News and More
Related News Releases
No news release information available for 1R21CA246457-01A1
History
No Historical information available for 1R21CA246457-01A1
Similar Projects
No Similar Projects information available for 1R21CA246457-01A1